Ventus Therapeutics U.S., Inc.
USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Ventus ranks #25,493 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 3 technology areas.
- #25,493
- of 49,997 US assignees by volume
- Top 28%
- by Innovation Score (43.4/100)
- 14.6
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R25493 · US Corporation #25,493 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 11 grants
- MID-PACK #25,493/49,997
- PHOTO-FINISH Valerion Therapeutics
- CPC-NARROW C07D · 3 areas
- INNOV-PAR 43.4/100
- CLAIMS-RICH 14.6 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2022–2025 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Valerion Therapeutics, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Ventus’s 43.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Ventus
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Ventus Therapeutics… · this assignee
Ventus Therapeutics… · this assignee
43 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Ventus's Innovation Score is 43.4/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Ventus?
Each dot is one of Ventus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ventus’s own 14.6 claims/patent is at or below the 18.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Ventus's grants concentrate
Ventus Therapeutics U.S., Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). By volume, Ventus sits between Valerion Therapeutics, LLC and Viega GmbH & Co. KG.
Ventus's three-year grant acceleration
Ventus Therapeutics U.S., Inc. shows 3 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Ventus's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Valerion Therapeu…
Valerion Therapeutics, LLC
11 patents
- Vanguard Group
Vanguard Group, Inc.
11 patents
- Vascular Access
Vascular Access Technologies, Inc.
11 patents
- Vascular Graft So…
Vascular Graft Solutions Ltd.
11 patents
- Veolia Nuclear So…
Veolia Nuclear Solutions, Inc.
11 patents
- Versana Micro
Versana Micro Inc.
11 patents
- Verwer Dahlias B V
Verwer Dahlias B.V.
11 patents
- Viega & KG
Viega GmbH & Co. KG
11 patents
- Ventus Therapeuti… ◀
Ventus Therapeutics U.S., Inc.
11 patents
What this shows Ventus holds 11 patents at rank #25,494, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Ventus
By rank, the assignees closest to #25,494 in granted patent volume.
- Valerion Therapeutics, LLC #25,490 · 11 patents
- Vanguard Group, Inc. #25,491 · 11 patents
- Vascular Access Technologies, Inc. #25,492 · 11 patents
- Vascular Graft Solutions Ltd. #25,493 · 11 patents
- Veolia Nuclear Solutions, Inc. #25,495 · 11 patents
- Versana Micro Inc. #25,496 · 11 patents
- Verwer Dahlias B.V. #25,497 · 11 patents
- Viega GmbH & Co. KG #25,498 · 11 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Ventus's primary technology class.
Ventus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
43 Top 28% higher than 72% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 9.1% |
| 2023 | 1 | 9.1% |
| 2024 | 1 | 9.1% |
| 2025partial year | 8 | 72.7% |
Which technologies does Ventus Therapeutics U.S., Inc. patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Ventus Therapeutics U.S., Inc.'s patent record in context - here's where to go next.
- Ventus Therapeutics U.S., Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #25,493 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Ventus Therapeutics U.S., Inc. against Valerion Therapeutics, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 43.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.